185 related articles for article (PubMed ID: 15598770)
21. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M; Walker-Corkery E; Barry MJ
J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer screening in the workplace. Employer costs.
Snyder C; Schrammel PN; Griffiths CB; Griffiths RI
AAOHN J; 1998 Aug; 46(8):379-84. PubMed ID: 9748918
[TBL] [Abstract][Full Text] [Related]
23. False-positive cancer screens and health-related quality of life.
McGovern PM; Gross CR; Krueger RA; Engelhard DA; Cordes JE; Church TR
Cancer Nurs; 2004; 27(5):347-52. PubMed ID: 15525861
[TBL] [Abstract][Full Text] [Related]
24. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Andriole GL
Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
[TBL] [Abstract][Full Text] [Related]
25. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
Taylor KL; Shelby R; Gelmann E; McGuire C
J Natl Cancer Inst; 2004 Jul; 96(14):1083-94. PubMed ID: 15265970
[TBL] [Abstract][Full Text] [Related]
26. Cancer: to screen or not to screen? A payer's perspective.
Amundson EP
S D Med; 2010; Spec No():72. PubMed ID: 20397494
[No Abstract] [Full Text] [Related]
27. Cumulative incidence of false-positive results in repeated, multimodal cancer screening.
Croswell JM; Kramer BS; Kreimer AR; Prorok PC; Xu JL; Baker SG; Fagerstrom R; Riley TL; Clapp JD; Berg CD; Gohagan JK; Andriole GL; Chia D; Church TR; Crawford ED; Fouad MN; Gelmann EP; Lamerato L; Reding DJ; Schoen RE
Ann Fam Med; 2009; 7(3):212-22. PubMed ID: 19433838
[TBL] [Abstract][Full Text] [Related]
28. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
29. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Oken MM; Marcus PM; Hu P; Beck TM; Hocking W; Kvale PA; Cordes J; Riley TL; Winslow SD; Peace S; Levin DL; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Dec; 97(24):1832-9. PubMed ID: 16368945
[TBL] [Abstract][Full Text] [Related]
30. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
31. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
Grubb RL; Pinsky P; Prorok PC; Andriole GL
Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
[TBL] [Abstract][Full Text] [Related]
32. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial.
Miller AB; Madalinska JB; Church T; Crawford D; Essink-Bot ML; Goel V; de Koning HJ; Määttänen L; Pentikäinen T
Eur J Cancer; 2001 Nov; 37(17):2154-60. PubMed ID: 11677101
[TBL] [Abstract][Full Text] [Related]
34. Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient.
Sharma A; Hostetter J; Morrison J; Wang K; Siegel E
J Digit Imaging; 2016 Apr; 29(2):160-4. PubMed ID: 26385814
[TBL] [Abstract][Full Text] [Related]
35. Cost of pretherapeutic staging of patients with colorectal cancer metastases in a French population.
Lejeune C; Logé P; Arveux P; Velten M; Jolly D; Woronoff-Lemsi MC; Guillemin F
Clin Res Hepatol Gastroenterol; 2011 May; 35(5):399-407. PubMed ID: 21317060
[TBL] [Abstract][Full Text] [Related]
36. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
[TBL] [Abstract][Full Text] [Related]
37. CT screening for comorbid disease in patients with prostatic carcinoma: is it cost-effective?
Forman HP; Heiken JP; Brink JA; Glazer HS; Fox LA; McClennan BL
AJR Am J Roentgenol; 1994 May; 162(5):1125-8; discussion 1129-30. PubMed ID: 8165996
[TBL] [Abstract][Full Text] [Related]
38. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.
Tammemagi MC; Freedman MT; Pinsky PF; Oken MM; Hu P; Riley TL; Ragard LR; Berg CD; Prorok PC
J Thorac Oncol; 2009 Jun; 4(6):710-21. PubMed ID: 19404219
[TBL] [Abstract][Full Text] [Related]
39. [Computed tomography screening for lung cancer].
Lazor R; Cornuz J; Lovis A; Nicod LP
Rev Med Suisse; 2012 Nov; 8(363):2206-11. PubMed ID: 23240295
[TBL] [Abstract][Full Text] [Related]
40. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
Kramer BS; Gohagan J; Prorok PC; Smart C
Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
